Showing 2331-2340 of 3329 results for "".
- AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinibhttps://practicaldermatology.com/news/ad-vise-better-patient-outcomes-tied-to-achieving-mda-at-6-months/2486433/Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the r
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- MDsave Partners with CareCredithttps://practicaldermatology.com/news/mdsave-partners-with-carecredit/2457505/MDsave is partnering with CareCredit to bring easy healthcare financing to their mission of providing better cost transparency to patients. As consumers face ever increasing healthcare costs, CareCredit, a Synchrony solution, offers patients the ability to pay over time for deductibles, co-pays,
- MDRejuvena Launches Vivatia Skin Lightening Product Line in UShttps://practicaldermatology.com/news/mdrejuvena-launches-vivatia-skin-lightening-product-line-in-us/2458014/MDRejuvena, Inc., has launched the Vivatia skin lightening product line in the US. Vivatia incorporates a patented, proprietary foam technology that enhances the dispersion and absorption of active ingredients into the skin. Vivatia has been clinically studied and proven effective for hyperpigmen
- MDRejuvena Launches Novel Product Line Focused on Skin Healthhttps://practicaldermatology.com/news/mdrejuvena-launches-novel-product-line-focused-on-skin-health/2458978/MDRejuvena, Inc. launched its novel, proprietary product line at the American Academy of Dermatology Meeting in San Francisco. MDRejuvena's product line, designed to rejuvenate, enhance, and maintain skin health, incorporates Phytochromatic MDT Complex, a proprietary, patented, plant-derived
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://practicaldermatology.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- Dr. Lisa Swanson Presents on Communication, Therapeutics, and Confidence in Treating Children at Noahhttps://practicaldermatology.com/news/dr-lisa-swanson-presents-on-communication-therapeutics-and-confidence-in-treating-children-at-noah/2486876/At the 67th Noah Worcester Dermatological Society Annual Meeting, Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, delivered the Alfred L. Weiner Lecture titled “Afraid to Treat Kids? Here are some Pearls to Help!” The session focused on practical, clinic-ready stra
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://practicaldermatology.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De